Gene therapy remains one of the most heavily invested areas of research and development in the medical field. With the promise of producing a novel drug to target poorly treated diseases, we’re seeing record levels of funding targeting up-and-coming pharmaceutical and biotech companies looking to find the next ‘million dollar’ drug.

With over 70 gene therapy trials currently underway in Europe alone, we know from our research the range of challenges associated with ultimately gaining that coveted approval, namely bringing together comprehensive CMC packages, successfully designing clinical trials, and understanding the intricacies of regulatory requirements and interactions. On this, the expertise and flexibility contract service providers can deliver when partnering with gene therapy companies can be the difference between success with the huge potential financial returns it brings and losing ground on the competition.

Join forces with us at the 6^th Annual Gene Therapy for Rare Disorders Europe where senior decision-makers from companies heavily invested in the space will be looking overcome these bottlenecks by forging business connections with organisations likely to help them beat the competition.